RxDB
ICD-10-PCS Codes Browse (Tables)

ICD-10 PCS – Browse (Tables)

Code Title
– Top Categories
X New Technology
XW Anatomical Regions
XW0 Introduction New Technology, Anatomical Regions, Introduction
XW03 Peripheral Vein
XW033 Percutaneous
XW0330 Brexanolone
XW03306 New Technology Group 6 Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW0332 Nerinitide
XW03326 New Technology Group 6 Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW0333 Durvalumab Antineoplastic
XW03336 New Technology Group 6 Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW0335 Narsoplimab Monoclonal Antibody
XW03357 New Technology Group 7 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW0336 Lefamulin Anti-infective
XW03366 New Technology Group 6 Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03367 New Technology Group 7 Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW0337 Coagulation Factor Xa, Inactivated
XW03372 New Technology Group 2 Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
XW03377 New Technology Group 7 Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW0338 Lurbinectedin
XW03387 New Technology Group 7 Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW0339 Defibrotide Sodium Anticoagulant
XW03392 New Technology Group 2 Introduction of Defibrotide Sodium Anticoagulant into Peripheral Vein, Percutaneous Approach, New Technology Group 2
XW03396 New Technology Group 6 Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033A Bezlotoxumab Monoclonal Antibody
XW033A3 New Technology Group 3 Introduction of Bezlotoxumab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033A6 New Technology Group 6 Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033A7 New Technology Group 7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033B Cytarabine and Daunorubicin Liposome Antineoplastic
XW033B3 New Technology Group 3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033B6 New Technology Group 6 Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033B7 New Technology Group 7 Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033C Eculizumab
XW033C6 New Technology Group 6 Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033C7 New Technology Group 7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033D Atezolizumab Antineoplastic
XW033D6 New Technology Group 6 Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033E Remdesivir Anti-infective
XW033E5 New Technology Group 5 Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033E6 New Technology Group 6 Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033F Other New Technology Therapeutic Substance
XW033F3 New Technology Group 3 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033F5 New Technology Group 5 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033F6 New Technology Group 6 Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G Plazomicin Anti-infective
XW033G4 New Technology Group 4 Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4
XW033G5 New Technology Group 5 Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033G6 New Technology Group 6 Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G7 New Technology Group 7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033H Synthetic Human Angiotensin II
XW033H4 New Technology Group 4 Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
XW033H5 New Technology Group 5 Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033H6 New Technology Group 6 Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H7 New Technology Group 7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033J Tisagenlecleucel Immunotherapy
XW033J7 New Technology Group 7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K Fosfomycin Anti-infective
XW033K5 New Technology Group 5 Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033K7 New Technology Group 7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033L CD24Fc Immunomodulator
XW033L6 New Technology Group 6 Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033L7 New Technology Group 7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033M Brexucabtagene Autoleucel Immunotherapy
XW033M7 New Technology Group 7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033N Meropenem-vaborbactam Anti-infective
XW033N5 New Technology Group 5 Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033N7 New Technology Group 7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033Q Tagraxofusp-erzs Antineoplastic
XW033Q5 New Technology Group 5 Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033S Iobenguane I-131 Antineoplastic
XW033S5 New Technology Group 5 Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033U Imipenem-cilastatin-relebactam Anti-infective
XW033U5 New Technology Group 5 Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033W Caplacizumab
XW033W5 New Technology Group 5 Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5